Eisai Plans Buy Of AkaRx Of U.S., Liver Dysfunction Drug Developer
This article was originally published in PharmAsia News
Eisai says it plans to buy AkaRx, a U.S.-based biotech, for $255 million
You may also be interested in...
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.
Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.